Adam F " I Believe ZIOP Wins The Study,& Positve Trend Towards Longer Survival" posted here.
The Street 3/1/13
Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta
By Adam Feuerstein
I believe Ziopharm wins with the palifosfamide sarcoma study, meaning a statistically significant improvement in progression-free survival -- the study's primary endpoint. I'll predict a positive trend towards longer survival favoring palifosfamide.
Adam is an idiot. He was saying ZIOPHARM had no chance with Pali due to his stupid "rule" and now he's changed his mind? He's full of #$%$ and his name isn't worthy of this board. I remember his BS on CLDA and he was totally wrong then. This time he happens to be right after being wrong with his stupid "rule". GO AWAY!